
Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target
Rhythm Pharmaceuticals (RYTM) Analyst Ratings
Bulls say
Rhythm Pharmaceuticals Inc. has a positive outlook due to strong revenue performance, recording $41.8 million in top-line revenue for 4Q24, significantly surpassing forecasts of $35.9 million. The anticipation of positive Phase 3 trial results for its MC4R agonist, IMCIVREE, particularly in the treatment of hypothalamic obesity, is expected to enhance peak sales potential further. Additionally, the company's stock has demonstrated resilience and strong performance relative to the S&P 500 and XBI indices, reaching a two-year high of $67 in early November 2024, bolstered by successful product launches and impressive clinical data.
Bears say
Rhythm Pharmaceuticals has accumulated substantial losses and is not expected to achieve profitability for several years, raising concerns about its financial sustainability. Key risks include the potential failure to produce favorable data from clinical trials, challenges in obtaining regulatory approvals for setmelanotide in additional indications, and setbacks related to earlier-stage candidates, all of which could hinder commercial success. Furthermore, a lower-than-anticipated number of treatable patients for related diseases and a slow sales ramp for IMCIVREE may materially impact revenue projections, contributing to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Rhythm Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Rhythm Pharmaceuticals (RYTM) Analyst Forecast & Price Prediction
Start investing in Rhythm Pharmaceuticals (RYTM)
Order type
Buy in
Order amount
Est. shares
0 shares